Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054883 | 1.00 | LMNA (0.43) | LMNAEPHA2KDREPHB4MAPT | |
| SCHEMBL3052199 | 0.77 | MAPT (0.46) | LMNAMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10276991 | 0.74 | MAPT (0.45) | LMNAMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3061283 | 0.73 | LMNA (0.58) | LMNAEPHA2KDRMAPTSMN1; SMN2 | |
| SCHEMBL3051396 | 0.73 | TP53 (0.55) | LMNAEPHA2KDRMAPTSMN1; SMN2 | |
| SCHEMBL10277518 | 0.71 | MAPT (0.43) | LMNAMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3056104 | 0.71 | PIK3CD (0.48) | LMNAMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3059036 | 0.70 | TP53 (0.53) | LMNAEPHA2KDRMAPTSMN1; SMN2 | |
| SCHEMBL3051775 | 0.70 | MAPT (0.46) | KDRMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3055242 | 0.70 | SMN1; SMN2 (0.42) | LMNAKDRMAPTSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | claimed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | claimed |
| US-20090131445-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-05-21 | — | — | US | claimed |
| EP-1799689-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006044402-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | disclosed |
| US-20090131445-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | LMNA 1432/4885EPHA2 2387/4885KDR 2898/4885 |
| US-20090131445-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, RB1, CA5A | LMNA 1452/4885EPHA2 2736/4885KDR 3420/4885 |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | LMNA 1432/4885EPHA2 2387/4885KDR 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.